Trial Profile
Phase I single-ascending dose (SAD) trial of ARI 3037MO
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Nov 2012
Price :
$35
*
At a glance
- Drugs ARI 3037MO (Primary)
- Indications Dyslipidaemias
- Focus Adverse reactions; Pharmacokinetics
- Acronyms SAD
- 07 Nov 2012 Status changed from planning to completed, based on results reported in an Arisaph Pharmaceuticals media release.
- 23 Mar 2011 New trial record